CR20130133A - Composiciones de anticuerpo y mètodos de uso - Google Patents

Composiciones de anticuerpo y mètodos de uso

Info

Publication number: CR20130133A
Authority: CR; Costa Rica
Prior art keywords: methods; antibody compositions; antibody; compositions
Prior art date: 2010-09-29

Application number

CR20130133A

Other languages

English (en)

Inventor

Xiaocheng Chen

Mark S Dennis

Becket L Feierbach

Ashley E Fouts

Isidro Hotzel

Bing Li

Jo-Anne Hongo

Rajesh Vij

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-29

Filing date

2013-03-21

Publication date

2013-08-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45890018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130133(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-21 Application filed by Genentech Inc filed Critical Genentech Inc

2013-08-29 Publication of CR20130133A publication Critical patent/CR20130133A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/089—Cytomegalovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CR20130133A 2010-09-29 2013-03-21 Composiciones de anticuerpo y mètodos de uso CR20130133A (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US38773510P	2010-09-29	2010-09-29
US38772510P	2010-09-29	2010-09-29
US201161504056P	2011-07-01	2011-07-01
PCT/US2011/054092 WO2012047732A2 (en)	2010-09-29	2011-09-29	Antibody compositions and methods of use

Publications (1)

Publication Number	Publication Date
CR20130133A true CR20130133A (es)	2013-08-29

Family

ID=45890018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20130133A CR20130133A (es)	2010-09-29	2013-03-21	Composiciones de anticuerpo y mètodos de uso

Country Status (21)

Country	Link
US (2)	US20120082666A1 (es)
EP (1)	EP2621533A4 (es)
JP (1)	JP2014501491A (es)
KR (1)	KR20130112879A (es)
CN (2)	CN103313727B (es)
AR (1)	AR083214A1 (es)
AU (1)	AU2011312425A1 (es)
BR (1)	BR112013007514A2 (es)
CA (1)	CA2811087A1 (es)
CL (1)	CL2013000868A1 (es)
CO (1)	CO6690799A2 (es)
CR (1)	CR20130133A (es)
EA (1)	EA201390467A1 (es)
EC (1)	ECSP13012536A (es)
IL (1)	IL225389A0 (es)
MA (1)	MA34541B1 (es)
MX (1)	MX2013002960A (es)
PE (1)	PE20140195A1 (es)
PH (1)	PH12013500616A1 (es)
SG (1)	SG188657A1 (es)
WO (1)	WO2012047732A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014024023A2 (pt) *	2012-03-28	2017-07-18	Genentech Inc	anticorpos idiotípicos anti-hcmv e usos dos mesmos
WO2014099908A1 (en) *	2012-12-17	2014-06-26	Genentech, Inc.	Methods for inhibiting viral infection in transplant patients
KR102218494B1 (ko)	2013-03-15	2021-02-19	인트린식 라이프사이언시스, 엘엘씨	항-헵시딘 항체 및 그의 용도
WO2014200898A2 (en)	2013-06-10	2014-12-18	Merck Sharp & Dohme Corp.	Cmv neutralizing antigen binding proteins
KR102332302B1 (ko)	2013-09-13	2021-12-01	제넨테크, 인크.	세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
SG10201802525QA (en)	2013-09-13	2018-04-27	Genentech Inc	Methods and compositions comprising purified recombinant polypeptides
AU2015321462B2 (en) *	2014-09-22	2020-04-30	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
WO2017032686A1 (en)	2015-08-21	2017-03-02	F. Hoffmann-La Roche Ag	Method for the reduction of host cell proteins in affinity chromatography
GB201607979D0 (en) *	2016-05-06	2016-06-22	Liverpool School Tropical Medicine	Monomeric proteins and uses thereof
JP7546485B2 (ja)	2018-10-25	2024-09-06	Ｋｍバイオロジクス株式会社	改変ＣＭＶｇＢタンパク質及びこれを含むＣＭＶワクチン
CA3230585A1 (en) *	2021-09-03	2023-03-09	Domenico Tortorella	Anti-hcmv antibodies and antigen-binding fragments thereof
WO2024229365A1 (en) *	2023-05-03	2024-11-07	The University Of Chicago	Growth hormone targeting polypeptides
CN119269807A (zh) *	2024-11-26	2025-01-07	华润昂德生物药业有限公司	一种基于SPR检测EPO与其受体EpoR的体外结合活性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08506325A (ja) *	1993-01-28	1996-07-09	サンドファーマスーティカルコーポレーション	サイトメガロウイルスに対するヒトモノクローナル抗体
WO1996006625A1 (en) *	1994-08-26	1996-03-07	Eli Lilly And Company	Antibody constructs with cdr switched variable regions
US6875433B2 (en) *	2002-08-23	2005-04-05	The United States Of America As Represented By The Secretary Of The Army	Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
WO2006044643A2 (en) *	2004-10-15	2006-04-27	Seattle Genetics, Inc.	Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2618796C (en) *	2005-08-11	2018-01-02	Arpi Matossian-Rogers	Peptides for treatment and diagnosis of autoimmune disease
US20080003605A1 (en) *	2006-05-24	2008-01-03	The University Of Chicago	Microarray analysis of light chain variable gene expression and methods of use
EP3031469B1 (en) *	2006-06-07	2023-08-23	The Trustees Of Princeton University	Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ES2363992T3 (es) *	2006-12-15	2011-08-22	Ribovax Biotechnologies Sa	Anticuerpos frente a citomegalovirus humano (cmvh).
US8124093B2 (en) *	2008-07-16	2012-02-28	Institute For Research In Biomedicine	Human cytomegalovirus neutralizing antibodies and use thereof

2011
- 2011-09-29 CN CN201180057119.7A patent/CN103313727B/zh not_active Expired - Fee Related
- 2011-09-29 WO PCT/US2011/054092 patent/WO2012047732A2/en not_active Ceased
- 2011-09-29 CN CN201510363420.0A patent/CN104945505A/zh active Pending
- 2011-09-29 JP JP2013531893A patent/JP2014501491A/ja active Pending
- 2011-09-29 EA EA201390467A patent/EA201390467A1/ru unknown
- 2011-09-29 MX MX2013002960A patent/MX2013002960A/es not_active Application Discontinuation
- 2011-09-29 MA MA35760A patent/MA34541B1/fr unknown
- 2011-09-29 BR BR112013007514-7A patent/BR112013007514A2/pt not_active IP Right Cessation
- 2011-09-29 US US13/248,998 patent/US20120082666A1/en not_active Abandoned
- 2011-09-29 CA CA2811087A patent/CA2811087A1/en not_active Abandoned
- 2011-09-29 AU AU2011312425A patent/AU2011312425A1/en not_active Abandoned
- 2011-09-29 EP EP11831352.7A patent/EP2621533A4/en not_active Withdrawn
- 2011-09-29 KR KR1020137007881A patent/KR20130112879A/ko not_active Withdrawn
- 2011-09-29 AR ARP110103598A patent/AR083214A1/es not_active Application Discontinuation
- 2011-09-29 PH PH1/2013/500616A patent/PH12013500616A1/en unknown
- 2011-09-29 PE PE2013000655A patent/PE20140195A1/es not_active Application Discontinuation
- 2011-09-29 SG SG2013022751A patent/SG188657A1/en unknown
2013
- 2013-03-21 IL IL225389A patent/IL225389A0/en unknown
- 2013-03-21 CR CR20130133A patent/CR20130133A/es unknown
- 2013-03-28 CL CL2013000868A patent/CL2013000868A1/es unknown
- 2013-03-28 EC ECSP13012536 patent/ECSP13012536A/es unknown
- 2013-04-12 CO CO13095273A patent/CO6690799A2/es unknown
2014
- 2014-12-19 US US14/577,991 patent/US20150376265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1189501A1 (zh)	2014-06-13
WO2012047732A2 (en)	2012-04-12
US20150376265A1 (en)	2015-12-31
IL225389A0 (en)	2013-06-27
ECSP13012536A (es)	2013-06-28
WO2012047732A3 (en)	2013-05-30
PH12013500616A1 (en)	2013-06-03
MX2013002960A (es)	2013-05-09
SG188657A1 (en)	2013-05-31
BR112013007514A2 (pt)	2019-09-24
EA201390467A1 (ru)	2013-11-29
EP2621533A2 (en)	2013-08-07
CN103313727A (zh)	2013-09-18
CN103313727B (zh)	2015-07-22
EP2621533A4 (en)	2015-06-17
AR083214A1 (es)	2013-02-06
CO6690799A2 (es)	2013-06-17
JP2014501491A (ja)	2014-01-23
CL2013000868A1 (es)	2014-01-24
AU2011312425A1 (en)	2013-04-11
KR20130112879A (ko)	2013-10-14
PE20140195A1 (es)	2014-02-24
MA34541B1 (fr)	2013-09-02
CN104945505A (zh)	2015-09-30
CA2811087A1 (en)	2012-04-12
US20120082666A1 (en)	2012-04-05

Publication	Publication Date	Title
CR20130133A (es)	2013-08-29	Composiciones de anticuerpo y mètodos de uso
PT2585437E (pt)	2014-04-29	Compostos de tioacetato, composições e métodos de uso
CO7020870A2 (es)	2014-08-11	Anticuerpos anti-htra1 y métodos de uso
BR112014028366A2 (pt)	2017-06-27	anticorpos anti-ly6e e imunoconjugados e métodos de uso
BR112013006016A2 (pt)	2016-06-07	compostos de azabenzotiazol, composições e métodos de uso
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
BR112014012590A2 (pt)	2017-06-20	anticorpos anti-cd98 e métodos de uso dos mesmos
BRPI1014544A8 (pt)	2016-10-11	anticorpos anti-il-17f e metodos de uso dos mesmos
IL244000A0 (en)	2016-04-21	Anti-fap antibodies and methods of use
CO6870005A2 (es)	2014-02-20	Composición anti-cgrp y uso de las mismas
BR112013014321A2 (pt)	2019-09-24	moduladores inovadores e métodos de uso
BRPI1012676A2 (pt)	2016-04-05	anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt)	2016-07-26	anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BR112014002716A2 (pt)	2017-06-13	anticorpos anti-poliubiquitina e métodos de uso
BR112013010988A2 (pt)	2016-07-26	composição fluída e uso
CO7000773A2 (es)	2014-07-21	Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112013010331A2 (pt)	2016-07-05	composições adesivas crepadas e métodos de uso dessas composições
CO6862148A2 (es)	2014-02-10	Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas
BR112013011448A2 (pt)	2016-08-09	composto, composição farnmacêutica, e, uso do composto
PL2990421T3 (pl)	2018-08-31	Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
PT2424372T (pt)	2018-04-19	Composições antimicrobianas e métodos de uso relacionados
BR112014014547A2 (pt)	2017-06-13	compostos antagonistas de e-selectina, composições e métodos de uso
PL2490720T3 (pl)	2020-08-24	Cząsteczki przeciwciał anty-gcc oraz powiązane kompozycje i sposoby
ME03766B (me)	2021-04-20	Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
BRPI0915928A2 (pt)	2015-11-03	composições e métodos de uso para anticorpos terapêuticos